Table 4 The primary Pharmacokinetic parameters of oral DTX granules (n = 4).
From: Influences of formulations and administration routes on docetaxel tissue distribution in mice
Parameter | Plasma | Brain | Heart | Kidneys | Liver | Lung | Lymph Node | Small intestine | Spleen | Stomach |
|---|---|---|---|---|---|---|---|---|---|---|
Cmax (ng/mL) | 50.2 ± 32.8 | 35.0 ± 24.4 | 102 ± 53.6 | 437 ± 141 | 539 ± 233 | 250 ± 130 | 1080 ± 716 | 66,628 ± 17,206 | 371 ± 266 | 196,141 ± 36,130 |
Tmax (h) | 2.00 ± 0.00 | 1.25 ± 0.500 | 1.50 ± 0.577 | 1.75 ± 0.500 | 1.75 ± 0.500 | 1.38 ± 0.750 | 2.00 ± 0.00 | 0.625 ± 0.250 | 1.75 ± 0.500 | 1.38 ± 0.750 |
AUClast (h ng/mL) | 109 ± 52.7 | 34.5 ± 15.6 | 303 ± 113 | 1115 ± 374 | 713 ± 499 | 786 ± 238 | 2329 ± 1217 | 101,414 ± 18,868 | 825 ± 411 | 581,187 ± 41,253 |
AUCinf (h ng/mL) | 81.4 ± 35.3* | 77.6 ± 58.1 | 329 ± 147 | 1978 ± 1788 | 998 ± 588 | 1401 ± 619 | 2489 ± 1136 | 115,971 ± 31,571 | 887 ± 482 | 623,436 ± 67,524 |
t1/2 (h) | 1.18 ± 0.235 | 2.48 ± 2.68 | 1.88 ± 0.371 | 4.07 ± 5.85 | 0.472 ± 0.346 | 5.09 ± 3.28 | 1.29 ± 0.259 | 2.63 ± 1.14 | 1.57 ± 0.739 | 1.50 ± 0.618 |
Vd/F (mL/kg) | 111,934 ± 25,427 | / | / | / | / | / | / | / | / | / |
CL/F (mL/h/kg) | 68,490 ± 28,552 | / | / | / | / | / | / | / | / | |
T/P ratio | / | 0.317 | 2.78 | 10.2 | 6.54 | 7.21 | 21.4 | 930 | 7.57 | 5332 |
F(%) | 6.93 ± 1.72% | / | / | / | / | / | / | / | / | / |
